Unbelievable New Discovery: Mounjaro's Power to Reverse Liver Disease
Belinda Whitlock, a 55-year-old mother of four, was diagnosed with advanced liver fibrosis, a condition linked to obesity and long-term inflammation. Her story is one of hope and resilience, as she battled fatigue, nausea, and unexplained stomach pain, initially dismissed as menopause symptoms. Despite hormone replacement therapy, her health worsened, and she faced a grim prognosis, recalling her mother's tragic death from liver cancer at 46.
Belinda's drastic lifestyle changes, including a Mediterranean diet, coffee, and no takeaways, yielded results. However, her liver scans showed little improvement. Seeking a new approach, she turned to GLP-1 weight-loss drugs, paying hundreds of pounds monthly for a private prescription. The results were astonishing: she lost five stone, her BMI dropped to 31, and her liver fibrosis reversed.
This discovery is groundbreaking, as experts like Professor Philip Newsome highlight the alarming rise in liver disease and the promising use of weight-loss drugs to reverse liver damage. The condition progresses through four stages, starting with excess fat, inflammation, and scarring. The British Liver Trust estimates 80% of those with fatty liver disease are undiagnosed, and without treatment, it can lead to cirrhosis, a non-reversible end-stage liver disease.
Mounjaro, a GLP-1 drug, has shown remarkable results for patients like Gillian Scott, a 57-year-old civil servant with cirrhosis due to type 2 diabetes and obesity. After switching to Mounjaro, she lost nine stone and her condition improved from cirrhosis to fibrosis. A 2024 study in the New England Journal Of Medicine revealed that 62% of patients on the highest dose of Mounjaro saw their fatty liver disease resolve, with liver function returning to normal.
Professor Newsome emphasizes the potential of GLP-1 drugs beyond weight loss, suggesting a direct effect on immune cells in the liver. However, these drugs are not yet approved on the NHS for liver disease, causing financial strain for patients like Belinda, who has dipped into her pension to afford the treatment. The NHS's delay in recognizing the benefits of these drugs is a pressing issue, as they could be life-saving for many.
